A model of the health and economic impact of posttransfusion hepatitis C: application to cost‐effectiveness analysis of further expansion of HCV screening protocols

BACKGROUND: Cost‐effectiveness analyses are needed to decide the value of further expansion of the screening protocols for HCV in blood donors. However, such analyses are hampered by imperfect knowledge of the health and economic repercussions of posttransfu‐sion hepatitis C (PTHC).

[1]  T. Layden,et al.  Impact of alcohol on the histological and clinical progression of Hepatitis C infection , 1998, Hepatology.

[2]  C. Hunt,et al.  Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. , 1997, Digestive diseases and sciences.

[3]  S. Kleinman,et al.  Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study , 1995, Transfusion.

[4]  A. Alberti,et al.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. , 1992 .

[5]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[6]  C. Gil,et al.  Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.

[7]  A. Muñoz,et al.  The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.

[8]  S. Vento,et al.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C , 2000, Journal of viral hepatitis.

[9]  R. Koretz,et al.  Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.

[10]  J. Ludwig,et al.  The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.

[11]  Iglehart Jk,et al.  The American health care system--expenditures. , 1999 .

[12]  L. Corey,et al.  Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. , 1994, The Journal of infectious diseases.

[13]  D. Casarett,et al.  Have We Treated AIDS Too Well? Rationing and the Future of AIDS Exceptionalism , 1998, Annals of Internal Medicine.

[14]  A. Burt,et al.  Outcome of post-transfusion hepatitis C: disease severity in blood-component recipients and their implicated donors. , 1997, QJM : monthly journal of the Association of Physicians.

[15]  E. Tanaka,et al.  The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses , 1996, Hepatology.

[16]  R. Zimmermann,et al.  A survey of blood component use in a German university hospital , 1997, Transfusion.

[17]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[19]  M C Weinstein,et al.  Gains in life expectancy from medical interventions--standardizing data on outcomes. , 1998, The New England journal of medicine.

[20]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[21]  S. Gordon,et al.  Clinical outcome of hepatitis C as a function of mode of transmission , 1998, Hepatology.

[22]  G. Corrao,et al.  Prognostic factors for long-term survival in cirrhotic patients after the first episode of liver decompensation. , 1997, Italian journal of gastroenterology and hepatology.

[23]  D. Mark,et al.  Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. , 1997, The New England journal of medicine.

[24]  E. Vamvakas,et al.  Long‐term survival after blood transfusion , 1994, Transfusion.

[25]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[26]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[27]  H. Bonkovsky,et al.  Reduction of health‐related quality of life in chronic hepatitis C and improvement with interferon therapy , 1999, Hepatology.

[28]  M. Pinzani,et al.  Long course and prognostic factors of virus-induced cirrhosis of the liver. , 1997, The American journal of gastroenterology.

[29]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[30]  Jennifer A. Roberts,et al.  Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal , 1995, Hepatology.

[31]  Terry Therneau,et al.  Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[32]  A. Pereira.  Cost‐effectiveness of transfusing virus‐inactivatedplasma instead of standard plasma , 1999, Transfusion.

[33]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[34]  S. Yagi,et al.  Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen , 1999, Journal of Clinical Microbiology.

[35]  J. Iglehart.  The American health care system--expenditures. , 1999, The New England journal of medicine.

[36]  D. Häussinger,et al.  Prognosis of chronic hepatitis c: Results of a large, prospective cohort study , 1998, Hepatology.

[37]  S. Kleinman,et al.  The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. , 1997, Transfusion medicine reviews.

[38]  F. Iber,et al.  Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .

[39]  E. Vamvakas,et al.  Epidemiology of blood transfusion , 1994, Transfusion.

[40]  J. Pawlotsky,et al.  Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: A French survey of 6,664 patients , 1997, Hepatology.

[41]  B. Portmann,et al.  Long-term outcome of hepatitis C infection after liver transplantation. , 1996, The New England journal of medicine.

[42]  J. Birkmeyer,et al.  Safety of the Blood Supply in the United States: Opportunities and Controversies , 1997, Annals of Internal Medicine.

[43]  O. Yokosuka,et al.  Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver disease , 1993, Hepatology.